Últimas noticias sobre Plus Therapeutics (NASDAQ:PSTV) Bolsa

Plus Therapeutics

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Plus Therapeutics Inc

POSTAL SVGS CHINA UNS/ADR by Postal Svgs Bk of China Ltd.

Postal Savings Bank Of China Co Ltd

<p>Stephens &amp; Co.  analyst Ben Bienvenu   maintains Ingredion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) with a Equal-Weight and lowers the price target from $155 to $150.</p>


News

Price Target

Analyst Ratings

INGR

Stephens & Co. Maintains Equal-Weight on Ingredion, Lowers Price Target to $150

WIIM

RXO shares are trading lower. The company reported Q4 financial results.

NOV shares are trading higher after the company reported better-than-expected Q4 financial results.

<p>Baird  analyst Jeffrey Meuler   maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Outperform and raises the price target from $579 to $605.</p>


Baird Maintains Outperform on Gartner, Raises Price Target to $605

Griffon shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Tempus AI shares are trading higher after TD Cowen reinstated a Buy rating on the stock and announced a price target of $74.

New York Times shares are trading lower after the company reported Q4 financial results and missed its revenue estimate.

<p>Baird  analyst Jeffrey Meuler   maintains Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Neutral and lowers the price target from $1975 to $1775.</p>


FICO

Baird Maintains Neutral on Fair Isaac, Lowers Price Target to $1775

<p>Shares of Brazil based aircraft manufacturer <strong>Embraer SA</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) are trading <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">higher on Wednesday</a>.</p>
<p>Embraer Executive Jets, a division of Embraer, has reached a <a target="_blank" href="https://www.benzinga.com//node/43492884" rel="noreferrer noopener">major purchase agreement with </a><strong><a target="_blank" href="https://www.benzinga.com//node/43492884" rel="noreferrer noopener">Flexjet</a></strong><a target="_blank" href="https://www.benzinga.com//node/43492884" rel="noreferrer noopener">.</a></p>
<p>The new agreement is worth up to $7 billion, encompassing a firm order for 182 aircraft, along with 30 options, as well as an upgraded package of services and support.</p>
<p>The deal includes a range of Embraer business jets, including the Praetor 600, Praetor 500, and Phenom 300E models.</p>
<p>Valued at up to $7 billion based on current list prices, this is Flexjet&#8217;s largest order in its 30-year history, as well as Embraer&#8217;s biggest firm order for executive aircraft.</p>
<p>The partnership between Embraer and Flexjet began in 2003 with the launch of the legacy Executive jet. Flexjet&#8217;s newest acquisition will further enhance its growing global fleet.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43429620/triumph-group-reaches-3b-acquisition-deal-with-private-equity-investors" rel="noreferrer noopener">Triumph Group Agrees To Go Private In $3 Billion Acquisition Deal</a></strong></p>
<p>&#8220;Since 2003, we have accepted delivery of more than 150 Embraer aircraft,&#8221; said&nbsp;Flexjet CEO <strong>Michael Silvestro</strong>.</p>
<p>&#8220;Both the Praetor 500 and Praetor 600 are high performers in the Flexjet fleet. Praetor 600 was so well accepted in&nbsp;Europe, we opted to include it in our North American fleet in 2023, extending our Embraer fleet across two continents.&#8221;</p>
<p>Embraer delivered 75 aircraft in the fourth quarter of FY24, a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43036046/embraer-reached-75-deliveries-in-the-last-quarter-of-2024-for-a-total-of-206-new-aircraft-in-the-y" rel="noreferrer noopener">27% increase from the third quarter</a> of FY24. For the full year, deliveries increased 14% to 206 aircraft.</p>
<p><strong>Price Action</strong>: ERJ shares are trading higher by 11.8% at $44.55 at the last check Wednesday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/management/25/02/43429256/jeep-maker-stellantis-unveils-organizational-overhaul-stock-dips" target="_blank" rel="noreferrer noopener">Jeep Maker Stellantis Unveils Organizational Overhaul</a></strong></li>
</ul>
<p><em>Image via Shutterstock.</em></p>


Equities

Contracts

Movers

Trading Ideas

General

Embraer-Empresa Brasileira De Aeronautica

Embraer Lands Record $7 Billion Flexjet Order, Stock Jumps

Tempur Sealy International To Change Name To Somnigroup International

<p>Stephens &amp; Co.  analyst Mike Scialla   maintains Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) with a Overweight and lowers the price target from $21 to $20.</p>


TALO

Stephens & Co. Maintains Overweight on Talos Energy, Lowers Price Target to $20

<p>Baird  analyst Michael Halloran   maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and raises the price target from $139 to $148.</p>


Baird Maintains Outperform on Xylem, Raises Price Target to $148

<p>Stephens &amp; Co.  analyst Andrew Terrell   maintains RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) with a Equal-Weight and lowers the price target from $25 to $23.</p>


Stephens & Co. Maintains Equal-Weight on RBB Bancorp, Lowers Price Target to $23

<p>Baird  analyst Michael Halloran   maintains Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) with a Neutral and raises the price target from $106 to $114.</p>


Baird Maintains Neutral on Pentair, Raises Price Target to $114

Watching GeneDx Holdings Corp. Shares After Grizzly Reports Issues Bearish Report On Stock

Macro Economic Events

Econ #s

Economics

S&P Global Composite PMI For Jan 52.7 Vs 52.4 Est.; 55.4 Prior

<p>Stephens &amp; Co.  analyst Kyle Joseph   maintains Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) with a Overweight and raises the price target from $115 to $136.</p>


ENVA

Stephens & Co. Maintains Overweight on Enova International, Raises Price Target to $136

<p>Financial giants have made a conspicuous bearish move on Tesla. Our analysis of options history for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) revealed 23 unusual trades.</p>
<p>Delving into the details, we found 26% of traders were bullish, while 65% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $917,359, and 12 were calls, valued at $475,981.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $375.0 to $400.0 for Tesla during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Tesla options trades today is 9884.45 with a total volume of 3,034.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Tesla's big money trades within a strike price range of $375.0 to $400.0 over the last 30 days.</p>
<h3>Tesla 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738766774_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$18.5</td>
<td>$18.2</td>
<td>$18.5</td>
<td>$400.00</td>
<td>$370.0K</td>
<td>6.5K</td>
<td align="right">46</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$8.65</td>
<td>$8.5</td>
<td>$8.62</td>
<td>$385.00</td>
<td>$97.4K</td>
<td>5.9K</td>
<td align="right">468</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$8.25</td>
<td>$8.05</td>
<td>$8.1</td>
<td>$385.00</td>
<td>$90.5K</td>
<td>5.9K</td>
<td align="right">468</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$15.05</td>
<td>$14.65</td>
<td>$14.9</td>
<td>$375.00</td>
<td>$83.4K</td>
<td>2.9K</td>
<td align="right">101</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$7.25</td>
<td>$7.15</td>
<td>$7.18</td>
<td>$387.50</td>
<td>$71.8K</td>
<td>2.8K</td>
<td align="right">272</td>
</tr>
</tbody>
</table>
</p>
<h3>About Tesla</h3>
<p>Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and offer a robotaxi service. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.</p>
<p>After a thorough review of the options trading surrounding Tesla, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Tesla Standing Right Now?</h3>
<ul>
<li>With a volume of 2,125,098, the price of TSLA is down -1.34% at $386.94. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>Professional Analyst Ratings for Tesla</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $457.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $365.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Tesla, which currently sits at a price target of $430.<br />
&#x2A; Maintaining their stance, an analyst from Wedbush continues to hold a Outperform rating for Tesla, targeting a price of $550.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $440.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Tesla, targeting a price of $500. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Tesla options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

TSLA

Tesla Unusual Options Activity For February 05

S&P Global Services PMI For Jan 52.9 Vs 52.8 Est.; 56.8 Prior

<p>High-rolling investors have positioned themselves bearish on Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AVGO often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Broadcom. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 12% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $51,830, and 7 calls, totaling $478,206.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $190.0 to $235.0 for Broadcom over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Broadcom stands at 3190.8, with a total volume reaching 565.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Broadcom, situated within the strike price corridor from $190.0 to $235.0, throughout the last 30 days.</p>
<h3>Broadcom Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738766769_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$9.6</td>
<td>$9.05</td>
<td>$9.35</td>
<td>$230.00</td>
<td>$187.0K</td>
<td>1.8K</td>
<td align="right">1</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/07/25</td>
<td>$2.71</td>
<td>$2.69</td>
<td>$2.7</td>
<td>$235.00</td>
<td>$70.0K</td>
<td>7.4K</td>
<td align="right">340</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$11.4</td>
<td>$11.0</td>
<td>$11.4</td>
<td>$225.00</td>
<td>$57.0K</td>
<td>1.7K</td>
<td align="right">101</td>
</tr>
<tr>
<td>AVGO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$2.71</td>
<td>$2.64</td>
<td>$2.64</td>
<td>$235.00</td>
<td>$53.6K</td>
<td>7.4K</td>
<td align="right">340</td>
</tr>
<tr>
<td>AVGO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$230.00</td>
<td>$51.8K</td>
<td>2.9K</td>
<td align="right">113</td>
</tr>
</tbody>
</table>
</p>
<h3>About Broadcom</h3>
<p>Broadcom is the sixth-largest semiconductor company globally and has expanded into various software businesses, with over $30 billion in annual revenue. It sells 17 core semiconductor product lines across wireless, networking, broadband, storage, and industrial markets. It is primarily a fabless designer but holds some manufacturing in-house, like for its best-of-breed FBAR filters that sell into the Apple iPhone. In software, it sells virtualization, infrastructure, and security software to large enterprises, financial institutions, and governments.Broadcom is the product of consolidation. Its businesses are an amalgamation of former companies like legacy Broadcom and Avago Technologies in chips, as well as Brocade, CA Technologies, and Symantec in software.</p>
<p>After a thorough review of the options trading surrounding Broadcom, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Broadcom</h3>
<ul>
<li>With a volume of 1,855,928, the price of AVGO is up 3.39% at $229.96. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>Expert Opinions on Broadcom</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $255.33333333333334.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Broadcom, targeting a price of $260.<br />
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Broadcom, which currently sits at a price target of $260.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Broadcom, which currently sits at a price target of $246. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Broadcom, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AVGO

Broadcom's Options: A Look at What the Big Money is Thinking

Plus Therapeutics GAAP EPS of -$0.37 beats by $0.19, revenue of $1.45M beats by $0.31M

Plus Therapeutics ( ($PSTV) ) has released its Q3 earnings. Here is a breakdown of the information Plus Therapeutics presented to its investors. Pl...

Plus Therapeutics Advances Radiotherapeutics in Q3 2024

Analyst Sean Lee CFA from H.C. Wainwright maintained a Buy rating on Plus Therapeutics (PSTV – Research Report) and keeping the price target at $8....

Plus Therapeutics: Promising Growth and Stability Backed by Financial Strength and Clinical Innovations

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Plus Therapeutics (PSTV – Research Report). The associated price target i...

Positive Outlook for Plus Therapeutics: Strong Financial Support and Clinical Advancements Justify Buy Rating

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

CNSide Diagnostics, a wholly owned subsidiary of Plus Therapeutics (PSTV), will present data demonstrating the utility of the CNSide CSF Assay Plat...

Plus Therapeutics subsidiary to present data on CNSide CSF Assay Platform

CNSide Diagnostics will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform's utility in diagnosing and guiding clinical d...

Plus Therapeutics to present FORESEE clinical trial summary

Plus Therapeutics (PSTV) presented data updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium Obisbemeda in leptomeningeal dise...

Plus Therapeutics presents updated progress from its ReSPECT-LM Phase 1 trial

Plus Therapeutics (PSTV) announced the renewal of its Master Services Agreement, MSA, with Telix IsoTherapeutics Group. This MSA secures a reliable...

Plus Therapeutics expands strategic agreement with Telix IsoTherapeutics

Plus Therapeutics presented data on ReSPECT-LM Phase 1 trial

PSTV

Screenshot 2024-03-29 at 1.10.09 AM

Biotech

This Biotech Is Creating Targeted Radiotherapuetics For Some Of The Deadliest Cancers

Press Releases

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Earnings

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Health Care

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Comments

Plus Therapeutics

Noticias

Últimas noticias sobre Plus Therapeutics (NASDAQ:PSTV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL